Helicobacter pylori Eradication Does Not Change Circulating Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor Binding Protein 3 Levels in Patients With and Without Precancerous Gastric Lesions

• Published in: The American journal of the medical sciences 2013-11, Vol.346 (5), p.381-384
• Main Authors: Ustundag, Yücel, MD, Sahin, Hatice, MD, İlikhan, Sevil, MD, Dogan, Banu Gun, MD, Kokturk, Firuzan, MD, Kar, Fatih, MD
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents - therapeutic use; Case-Control Studies; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections - blood; Helicobacter Infections - drug therapy; Helicobacter pylori; Humans; Insulin-Like Growth Factor Binding Protein 3 - blood; Insulin-like growth factor binding protein-3; Insulin-Like Growth Factor I - metabolism; Insulin-like growth factor-1; Internal Medicine; Male; Middle Aged; Precancerous Conditions - blood; Precancerous Conditions - pathology; Premalignancy; Pyloric Antrum - metabolism; Pyloric Antrum - pathology; Stomach Neoplasms - blood; Stomach Neoplasms - pathology; Treatment Outcome
• ISSN: 0002-9629; 1538-2990
• DOI: 10.1097/MAJ.0b013e31827beed3

Abstract Background Circulating insulin-like growth factor (IGF)-1 and IGF-binding protein (IGFBP)-3 levels in the serum of Helicobacter pylori ( H pylori )-infected patients were investigated. Methods The study subjects consisted of 54 patients with H pylori infection, and the control subjects included 27 patients without H pylori infection. There was no statistical difference in the age and sex distributions between the study and control groups. Pretreatment serum levels of IGF-1 and IGFBP-3 were studied in all the subjects, including the healthy controls. H pylori eradication was achieved with a triple drug regimen for 2 weeks, and 1 month after this treatment, the serum levels of IGF-1 and IGFBP-3 were measured. The post-treatment H pylori status by a second gastroscopy, antral histopathology and urea breath testing was tested. Results The pretreatment serum levels of IGF-1 and IGFBP-3 of the study and control groups were not found to be different ( P > 0.05). H pylori treatment was successful in 42 patients in whom both serum IGF-1 and IGFBP-3 levels decreased with treatment, but the difference was only significant for the serum IGF-1 levels ( P : 0.04). There was no change in the serum levels of IGF-1 and IGFBP-3 in the 27 patients with precancereous gastric lesions before and after successful H pylori eradication. Conclusions No supporting evidence of a major interaction between H pylori infection itself and H pylori -associated premalignant lesions with circulating IGFBP-3 levels could be shown. Nevertheless, successful eradication of this microorganism led to a statistically significant decrease in serum IGF-1 levels.